这个药是很贵的。 在美国, 10万8千美元 一年,2017年。这是专利过期后,仿制药上市后的价钱。 2016年,14万6千美元一年。 在美国,也没几个人用得起。 2001年上市时是3万 一年,后来,药需求变大了,制药公司把价钱涨到 9万6千,一年。看看下面蓝色的那段,美国是有医生认为制药公司没道德。(美国,家庭年收入的中位数是5万1千美元,税后到手大概3万5千美元。)
However, prices for Gleevec and generic imatinib remained high 2 years later. In 2017, a month’s supply of Gleevec cost about $9000, and the cost of generic imatinib was about $8000. (Cost of imatinib still high despite generic options, team says, HematologyTimes)
The Arrival of Generic Imatinib Into the U.S. Market: An Educational ...www.ascopost.com/.../the-arrival-of-generic-imatinib-into-the-us-market-an-education...May 25, 2016 - Generic imatinib is available in Canada for $8,800/year and Gleevec is available for $38,000/year. In the United States, Gleevec is priced today at about$146,000/year. Thus, the “generic price” in the United States was in fact not much lower than the branded drug price.
Costs[size=14.805px]
[size=14.805px][size=13.9167px]
In 2013, more than 100 cancer specialists published a letter in Blood saying that the prices of many new cancer drugs, including imatinib, are so high that people in the United States couldn't afford them, and that the level of prices, and profits, was so high as to be immoral. Signatories of the letter included Brian Druker, Carlo Gambacorti-Passerini, and John Goldman, developers of imatinib. They wrote that in 2001, imatinib was priced at $30,000 a year, which was based on the price of interferon, then the standard treatment, and that at this price Novartis would have recouped its initial development costs in two years. They wrote that after unexpectedly becoming a blockbuster, Novartis increased the price to $92,000 per year in 2012, with annual revenues of $4.7 billion. Other physicians have complained about the cost.
Drucker himself, who led the clinical studies, never got a patent and never made money from it.
By 2016, the average wholesale price had increased to $120,000 a year, according to an analysis prepared for the Washington Post by Stacie Dusetzina of the University of North Carolina at Chapel Hill. When competitive drugs came on the market, they were sold at a higher price to reflect the smaller population,[clarification needed] and Novartis raised the price of Gleevec to match them.
A 2012 economic analysis funded by Bristol-Myers Squibb estimated that the discovery and development of imatinib and related drugs had created $143 billion in societal value at a cost to consumers of approximately $14 billion. The $143 billion figure was based on an estimated 7.5 to 17.5 year survival advantage conferred by imatinib treatment, and included the value (discounted at 3% per annum) of ongoing benefits to society after the imatinib patent expiration.
Prices for a 100 mg pill of Gleevec internationally range from $20 to $30,although generic imatinib is cheaper, as low as $2 per pill.